Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label dose-escalation study of LNP3794 in NRAS/KRAS-mutated advanced refractory solid tumors
NL-OMON55082Phase 1Active, not recruiting
- Sponsor
- Lupin Limited
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 3011441 in Nonhematologic neoplasms (4 arms), sponsored by Lupin Limited. Primary endpoint: Dose-limiting toxicities during cycle 1. Started Jan 2021; status: active, not recruiting.
02
Drugs
BI 3011441
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON55082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55082.